LivaNova to Announce Third-Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the.

Business Wire • Sep 23, 2026

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

LivaNova Director Sells 1,650 Shares for $131,500

The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.

The Motley Fool • Sep 11, 2026

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14, from 11:30 a.m.-12:05 p.m. EDT Baird 2026 Global Healthcare Conference on Tues., Sept. 15, from 11:25-11:55 a.m. EDT Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial.

Business Wire • Sep 3, 2026

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Seeking Alpha • Aug 24, 2026

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

Zacks Investment Research • Aug 6, 2026

LivaNova Q2 Earnings Call Highlights

LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.

MarketBeat • Aug 5, 2026

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared to the prior-year period Second-quarter U.S. GAAP diluted earnings per share of $1.93 and adjusted diluted earnings per sh.

Business Wire • Aug 5, 2026

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.

Zacks Investment Research • Aug 5, 2026